BioTuesdays

Tag - Kumaraguru Raja

Dermata Therapeutics Logo
Markets

Brookline starts Dermata Therapeutics at buy; PT $14

Brookline Capital Markets initiated coverage of Dermata Therapeutics (NASDAQ:DRMA) with a “buy” rating and a price target of $14. The stock closed at $4.87 on Sept. 20. Dermata is developing DMT310, a once-weekly...

September 21, 2021
Cyclacel Pharmaceuticals
Markets

Brookline starts Cyclacel Pharma at buy; PT $22

Brookline Capital Markets initiated coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $22 price target. The stock closed at $4.12 on May 18. Cyclacel is developing small molecule drugs targeting...

May 19, 2020
Edesa Biotech
Markets

Brookline starts Edesa Biotech at buy; PT $10

Brookline Capital Markets launched coverage of Edesa Biotech (NASDAQ:EDSA) with a “buy” rating and $10 price target. The stock closed at $2.16 on March 27. Edesa is developing EB01, a topical sPLA2 inhibitor that...

March 30, 2020
Hepion Pharmaceuticals
Markets

Brookline starts Hepion Pharma at buy; PT $12

Brookline Capital Markets launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $12 price target. The stock closed at $3.39 on Nov. 21. Hepion is developing CRV431, a novel pleiotropic...

November 22, 2019